Laboratory Biomarker Analysis + SARGRAMOSTIM + SVN53-67/M57-KLH PEPTIDE VACCINE + INCOMPLETE FREUND'S ADJUVANT + Temozolomide
2 treatments and conditions followed through the public trial records. Not medical advice. How a status is set
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| Laboratory Biomarker Analysis + SARGRAMOSTIM + SVN53-67/M57-KLH PEPTIDE VACCINE + INCOMPLETE FREUND'S ADJUVANT + Temozolomide for glioblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Laboratory Biomarker Analysis + SARGRAMOSTIM + SVN53-67/M57-KLH PEPTIDE VACCINE + INCOMPLETE FREUND'S ADJUVANT + Temozolomide for gliosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |